InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
61,692.52
(
1.32%
)
Post# of 252431
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: drbio45 post# 90353

Tuesday, 02/09/2010 6:56:10 AM

Tuesday, February 09, 2010 6:56:10 AM

Post# of 252431
I find it hard to believe that D-mab has a net negative effect on metastatic cancers, as the author of your post is suggesting. Possible, yes, but highly unlikely, IMHO.

As for the pricing decisions if D-mab should obtain approval in both cancer and osteoporosis: AMGN should be so lucky to have this dilemma!


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up